Sukumar Nagendran Sells 200,000 Shares of Taysha Gene Therapies (NASDAQ:TSHA) Stock

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) insider Sukumar Nagendran sold 200,000 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $4.71, for a total transaction of $942,000.00. Following the completion of the sale, the insider directly owned 1,006,439 shares of the company’s stock, valued at approximately $4,740,327.69. This trade represents a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Sukumar Nagendran also recently made the following trade(s):

• On Friday, November 28th, Sukumar Nagendran sold 110,125 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $4.75, for a total transaction of $523,093.75.
• On Monday, December 1st, Sukumar Nagendran sold 260,047 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $4.51, for a total value of $1,172,811.97.

Taysha Gene Therapies Stock Down 2.8%

Shares of NASDAQ:TSHA opened at $4.90 on Friday. The business’s 50 day moving average is $4.99 and its 200 day moving average is $3.93. The stock has a market cap of $1.34 billion, a P/E ratio of -14.85 and a beta of 1.02. Taysha Gene Therapies, Inc. has a 52-week low of $1.05 and a 52-week high of $6.02. The company has a quick ratio of 10.48, a current ratio of 10.48 and a debt-to-equity ratio of 0.23.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its earnings results on Tuesday, November 4th. The company reported ($0.09) earnings per share for the quarter, hitting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. Sell-side analysts predict that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on TSHA shares. Citigroup restated an “outperform” rating on shares of Taysha Gene Therapies in a report on Wednesday, November 5th. The Goldman Sachs Group set a $11.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, December 4th. UBS Group set a $11.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, December 4th. JMP Securities set a $8.00 target price on Taysha Gene Therapies in a research report on Wednesday, November 5th. Finally, Citizens Jmp boosted their price target on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “market outperform” rating in a research report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $10.67.

Hedge Funds Weigh In On Taysha Gene Therapies

Several institutional investors and hedge funds have recently bought and sold shares of TSHA. Vanguard Group Inc. increased its position in shares of Taysha Gene Therapies by 17.9% during the third quarter. Vanguard Group Inc. now owns 12,849,613 shares of the company’s stock worth $42,018,000 after purchasing an additional 1,955,486 shares in the last quarter. Octagon Capital Advisors LP grew its stake in Taysha Gene Therapies by 17.7% during the 2nd quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company’s stock worth $29,089,000 after buying an additional 1,892,500 shares during the last quarter. Jefferies Financial Group Inc. increased its position in Taysha Gene Therapies by 4,105.3% during the 2nd quarter. Jefferies Financial Group Inc. now owns 10,313,733 shares of the company’s stock valued at $23,825,000 after buying an additional 10,068,479 shares in the last quarter. Vestal Point Capital LP raised its stake in Taysha Gene Therapies by 83.3% in the third quarter. Vestal Point Capital LP now owns 5,500,000 shares of the company’s stock valued at $17,985,000 after buying an additional 2,500,000 shares during the last quarter. Finally, Polar Capital Holdings Plc raised its stake in Taysha Gene Therapies by 5.9% in the third quarter. Polar Capital Holdings Plc now owns 5,293,879 shares of the company’s stock valued at $17,311,000 after buying an additional 293,879 shares during the last quarter. 77.70% of the stock is owned by hedge funds and other institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.